PLUS1
110.39
1.61 (1.48%)
1.61 (1.48%)
Upgrade to Real-Time
Regular Market
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
Level 1 Starter
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Neurocrine Biosciences Inc | NBIX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 1.61 | 1.48% | 110.39 | 15:40:11 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 108.90 | 108.01 | 110.70 | 108.78 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 110.36 | 110.41 | 0.05 | - | - |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 6,201 | 466,222 | $ 109.50 | $ 51,052,843 | 862,430 | 72.14 - 136.265 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 15:40:15 | 2 | $ 110.40 | USD |
Neurocrine Biosciences Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 10.31B | 93.43M | 92.23M | $ 788.09M | $ 58.63M | 0.34 | 114.60 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Neurocrine Biosciences News
| Date | Time | Source | News Article |
|---|---|---|---|
| 1/12/2021 | 16:16 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 1/08/2021 | 07:30 | PR Newswire (US) | Neurocrine Biosciences Provides Preliminary Fourth Quarter.. |
| 1/04/2021 | 16:01 | PR Newswire (US) | Neurocrine Biosciences to Present at the 39th Annual J.P... |
| 12/22/2020 | 16:17 | GlobeNewswire Inc. | Voyager Therapeutics Provides Update on NBIb-1817 (VY-AADC).. |
| 12/02/2020 | 16:13 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 11/24/2020 | 08:03 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 11/19/2020 | 09:00 | PR Newswire (US) | Neurocrine Biosciences to Present at Upcoming Healthcare.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NBIX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 112.80 | 113.40 | 105.90 | 108.35 | 814,986 | -2.41 | -2.14% |
| 1 Month | 98.76 | 113.40 | 92.71 | 106.12 | 882,776 | 11.63 | 11.78% |
| 3 Months | 98.73 | 113.40 | 86.02 | 97.92 | 1,003,626 | 11.66 | 11.81% |
| 6 Months | 136.2618 | 136.2618 | 86.02 | 102.83 | 862,843 | -25.87 | -18.99% |
| 1 Year | 104.50 | 136.265 | 72.14 | 104.47 | 837,742 | 5.89 | 5.64% |
| 3 Years | 81.82 | 136.265 | 62.00 | 97.02 | 827,322 | 28.57 | 34.92% |
| 5 Years | 45.24 | 136.265 | 31.25 | 76.11 | 890,851 | 65.15 | 144.01% |
Neurocrine Biosciences Description
| Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome. |
